Resistance to aspirin and clopidogrel therapy

International Journal of Laboratory Hematology

Volumn 33, Issue 1, 2011, Pages 1-18

  Musallam, K M ^a   Charafeddine, K ^a   Bitar, A ^a   Khoury, M ^a   Assaad, S ^b   Beresian, J ^a   Alam, S ^a   Taher, A T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b NATIONAL COUNCIL FOR SCIENTIFIC RESEARCH   (Lebanon)

Author keywords

Aspirin; Clopidogrel; Resistance; Response; Review

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; THROMBOXANE; URIDINE DIPHOSPHATE; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DATA BASE; DRUG MECHANISM; DRUG RESISTANCE; DRUG TREATMENT FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; THERAPY RESISTANCE; TREATMENT RESPONSE;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 78651081167     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01268.x     Document Type: Review

References (111)

1. Agarwal S., Coakley M., Reddy K., Riddell A. & Mallett S. (2006) Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 105, 676-683.
2. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A. & Gachet C. (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Journal of Thrombosis and Haemostasis 3, 85-92.
3. Andre P., Delaney S.M., LaRocca T., Vincent D., DeGuzman F., Jurek M., Koller B., Phillips D.R. & Conley P.B. (2003) P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. Journal of Clinical Investigation 112, 398-406.
4. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Barrera Ramirez C., Sabate M., Fernandez C., Hernandez-Antolin R., Escaned J., Alfonso F. & Macaya C. (2004a) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? The Journal of Invasive Cardiology 16, 169-174.
5. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Banuelos C., Hernandez-Antolin R., Escaned J., Moreno R., Alfonso F. & Macaya C. (2004b) High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. European Heart Journal 25, 1903-1910.
6. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M.A., Bass T.A. & Macaya C. (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54, 2430-2435.
7. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., Zenni M.M., Guzman L.A., Bass T.A. & Costa M.A. (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115, 708-716.
8. Antithrombotic Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 324, 71-86.
9. Assadian A., Lax J., Meixner-Loicht U., Hagmuller G.W., Bayer P.M. & Hubl W. (2007) Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. Journal of Vascular Surgery 45, 1142-1147. discussion 1147.
10. Awtry E.H. & Loscalzo J. (2000) Aspirin. Circulation 101, 1206-1218.
11. Barone-Rochette G., Ormezzano O., Polack B., Vanzetto G., Bertrand B. & Machecourt J. (2008) Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases. Archives of Cardiovascular Diseases 101, 100-107.
12. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., Lafont A., Camoin L., Walter U. & Eigenthaler M. (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheterization and Cardiovascular Interventions 59, 295-302.
13. von Beckerath N., Pogatsa-Murray G., Wieczorek A., Sibbing D., Schomig A. & Kastrati A. (2006) Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thrombosis and Haemostasis 95, 910-911.
14. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I. & Schomig A. (2007) A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. European Heart Journal 28, 1814-1819.
15. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., Lee R., Bancroft J., MacEwan S., Shepherd J., Macfarlane P., Morris A., Jung R., Kelly C., Connacher A., Peden N., Jamieson A., Matthews D., Leese G., McKnight J., O'Brien I., Semple C., Petrie J., Gordon D., Pringle S. & MacWalter R. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. British Medical Journal 337, a1840.
16. ten Berg J.M., Gerritsen W.B., Haas F.J., Kelder H.C., Verheugt F.W. & Plokker H.W. (2002) High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thrombosis Research 105, 385-390.
17. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., Fabry-Ribaudo L., Hu T., Topol E.J. & Fox K.A. (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology 49, 1982-1988.
18. Bhatt D.L., Lincoff A.M., Gibson C.M., Stone G.W., McNulty S., Montalescot G., Kleiman N.S., Goodman S.G., White H.D., Mahaffey K.W., Pollack C.V. Jr, Manoukian S.V., Widimsky P., Chew D.P., Cura F., Manukov I., Tousek F., Jafar M.Z., Arneja J., Skerjanec S. & Harrington R.A. (2009) Intravenous platelet blockade with cangrelor during PCI. New England Journal of Medicine 361, 2330-2341.
19. Biondi-Zoccai G.G., Lotrionte M., Agostoni P., Abbate A., Fusaro M., Burzotta F., Testa L., Sheiban I. & Sangiorgi G. (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50, 279 patients at risk for coronary artery disease. European Heart Journal 27, 2667-2674.
20. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K. & Gurbel P.A. (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? Journal of the American College of Cardiology 49, 657-666.
21. Boncoraglio G.B., Bodini A., Brambilla C., Corsini E., Carriero M.R. & Parati E.A. (2009) Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clinical Neurology and Neurosurgery 111, 270-273.
22. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., Simeoni M.C., Barragan P., Dignat-George F. & Paganelli F. (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Journal of the American College of Cardiology 51, 1404-1411.
23. Borna C., Lazarowski E., van Heusden C., Ohlin H. & Erlinge D. (2005) Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thrombosis Journal 3, 10.
24. Bruno A., McConnell J.P., Cohen S.N., Tietjen G.E., Wallis R.A., Gorelick P.B. & Bang N.U. (2004) Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 35, 727-730.
25. Bucchi F., Bodzenta A., de Gaetano G. & Cerletti C. (1986) Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGF1 alpha in healthy subjects. Prostaglandins 32, 691-701.
26. Campbell C.L., Smyth S., Montalescot G. & Steinhubl S.R. (2007) Aspirin dose for the prevention of cardiovascular disease: a systematic review. Journal of the American Medical Association 297, 2018-2024.
27. Campo G., Valgimigli M., Gemmati D., Percoco G., Tognazzo S., Cicchitelli G., Catozzi L., Malagutti P., Anselmi M., Vassanelli C., Scapoli G. & Ferrari R. (2006) Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. Journal of the American College of Cardiology 48, 2178-2185.
28. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339.
29. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N. & FitzGerald G.A. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine 345, 1809-1817.
30. Chen W.H., Lee P.Y., Ng W., Tse H.F. & Lau C.P. (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. Journal of the American College of Cardiology 43, 1122-1126.
31. Chen W.H., Cheng X., Lee P.Y., Ng W., Kwok J.Y., Tse H.F. & Lau C.P. (2007) Aspirin resistance and adverse clinical events in patients with coronary artery disease. American Journal of Medicine 120, 631-635.
32. Christiaens L., Ragot S., Mergy J., Allal J. & Macchi L. (2008) Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagulation and Fibrinolysis 19, 235-239.
33. Cohen H.W., Crandall J.P., Hailpern S.M. & Billett H.H. (2008) Aspirin resistance associated with HbA1c and obesity in diabetic patients. Journal of Diabetes and Its Complications 22, 224-228.
34. Coleman J.L., Wang J.C. & Simon D.I. (2004) Determination of individual response to aspirin therapy using the Accumetrics Ultegra RFPA-ASA system. Point of Care 3, 77-82.
35. Cotter G., Shemesh E., Zehavi M., Dinur I., Rudnick A., Milo O., Vered Z., Krakover R., Kaluski E. & Kornberg A. (2004) Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? American Heart Journal 147, 293-300.
36. De Schryver E.L., Algra A. & van Gijn J. (2007) Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews 18, CD001820.
37. Derry S. & Loke Y.K. (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. British Medical Journal 321, 1183-1187.
38. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J. & Rupprecht H.J. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364, 331-337.
39. Dropinski J., Musial J., Sanak M., Wegrzyn W., Nizankowski R. & Szczeklik A. (2007) Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thrombosis Research 119, 301-303.
40. Dupont A.G., Gabriel D.A. & Cohen M.G. (2009) Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thrombosis Research 124, 6-13.
41. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q. & Yusuf S. (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105, 1650-1655.
42. Eikelboom J.W., Hankey G.J., Thom J., Claxton A., Yi Q., Gilmore G., Staton J., Barden A. & Norman P.E. (2005) Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. Journal of Thrombosis and Haemostasis 3, 2649-2655.
43. Eikelboom J.W., Hankey G.J., Thom J., Bhatt D.L., Steg P.G., Montalescot G., Johnston S.C., Steinhubl S.R., Mak K.H., Easton J.D., Hamm C., Hu T., Fox K.A. & Topol E.J. (2008) Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118, 1705-1712.
44. Englyst N.A., Horsfield G., Kwan J. & Byrne C.D. (2008) Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. Journal of Cerebral Blood Flow and Metabolism 28, 1196-1203.
45. European Stroke Prevention Study (1997) European Stroke Prevention Study 2. Efficacy and safety data. Journal of the Neurological Sciences 151(Suppl.), S1-S77.
46. Faraday N., Yanek L.R., Mathias R., Herrera-Galeano J.E., Vaidya D., Moy T.F., Fallin M.D., Wilson A.F., Bray P.F., Becker L.C. & Becker D.M. (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115, 2490-2496.
47. Fitzgerald D.J. & Maree A. (2007) Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007, 114-120.
48. Frolich J.C. (1997) A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends in Pharmacological Sciences 18, 30-34.
49. Frossard M., Fuchs I., Leitner J.M., Hsieh K., Vlcek M., Losert H., Domanovits H., Schreiber W., Laggner A.N. & Jilma B. (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110, 1392-1397.
50. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., Stellos K., May A.E. & Gawaz M. (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal 27, 2420-2425.
51. Gilard M., Arnaud B., Le Gal G., Abgrall J.F. & Boschat J. (2006) Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. Journal of Thrombosis and Haemostasis 4, 2508-2509.
52. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., Mansourati J., Mottier D., Abgrall J.F. & Boschat J. (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. Journal of the American College of Cardiology 51, 256-260.
53. Goodman T., Ferro A. & Sharma P. (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. British Journal of Clinical Pharmacology 66, 222-232.
54. Grundmann K., Jaschonek K., Kleine B., Dichgans J. & Topka H. (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. Journal of Neurology 250, 63-66.
55. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K. & Topol E.J. (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. American Journal of Cardiology 88, 230-235.
56. Gurbel P.A. & Tantry U.S. (2007) Clopidogrel resistance? Thrombosis Research 120, 311-321.
57. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z. & Tantry U.S. (2005a) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. Journal of the American College of Cardiology 46, 1827-1832.
58. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M. & Tantry U.S. (2005b) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111, 1153-1159.
59. Guthikonda S., Lev E.I., Patel R., DeLao T., Bergeron A.L., Dong J.F. & Kleiman N.S. (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. Journal of Thrombosis and Haemostasis 5, 490-496.
60. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J. & Algra A. (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367, 1665-1673.
61. Halushka M.K. & Halushka P.V. (2002) Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105, 1620-1622.
62. Harrison P. (2005) Platelet function analysis. Blood Reviews 19, 111-123.
63. Hart R.G., Leonard A.D., Talbert R.L., Pearce L.A., Cornell E., Bovill E. & Feinberg W.M. (2003) Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 23, 579-584.
64. Hennekens C.H., Schror K., Weisman S. & FitzGerald G.A. (2004) Terms and conditions: semantic complexity and aspirin resistance. Circulation 110, 1706-1708.
65. Hochholzer W., Trenk D., Frundi D., Blanke P., Fischer B., Andris K., Bestehorn H.P., Buttner H.J. & Neumann F.J. (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111, 2560-2564.
66. Inarrea P., Esteva F., Cornudella R. & Lanas A. (2000) Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scandinavian Journal of Gastroenterology 35, 242-246.
67. Ishizaki T. & Horai Y. (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Alimentary Pharmacology and Therapeutics 13(Suppl. 3), 27-36.
68. Kastrati A., von Beckerath N., Joost A., Pogatsa-Murray G., Gorchakova O. & Schomig A. (2004) Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110, 1916-1919.
69. Krasopoulos G., Brister S.J., Beattie W.S. & Buchanan M.R. (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. British Medical Journal 336, 195-198.
70. Lau W.C., Waskell L.A., Watkins P.B., Neer C.J., Horowitz K., Hopp A.S., Tait A.R., Carville D.G., Guyer K.E. & Bates E.R. (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107, 32-37.
71. Lau W.C., Gurbel P.A., Watkins P.B., Neer C.J., Hopp A.S., Carville D.G., Guyer K.E., Tait A.R. & Bates E.R. (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109, 166-171.
72. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F. & Lau C.P. (2005) Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. American Journal of Medicine 118, 723-727.
73. Lim P.W., Goh K.L. & Wong B.C. (2005) CYP2C19 genotype and the PPIs - focus on rabeprazole. Journal of Gastroenterology and Hepatology 20(Suppl.), S22-S28.
74. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A. & Diodati J.G. (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. European Heart Journal 28, 1702-1708.
75. Mammen E.F., Comp P.C., Gosselin R., Greenberg C., Hoots W.K., Kessler C.M., Larkin E.C., Liles D. & Nugent D.J. (1998) PFA-100 system: a new method for assessment of platelet dysfunction. Seminars in Thrombosis and Hemostasis 24, 195-202.
76. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D. & Hod H. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175.
77. Mehta J., Mehta P., Burger C. & Pepine C.J. (1978) Platelet aggregation studies in coronary artery disease. Past 4. Effect of aspirin. Atherosclerosis 31, 169-175.
78. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., Pulcinelli F.M., Cerletti C. & Rao A.K. (2005) Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis 3, 1309-1311.
79. Michos E.D., Ardehali R., Blumenthal R.S., Lange R.A. & Ardehali H. (2006) Aspirin and clopidogrel resistance. Mayo Clinic Proceedings 81, 518-526.
80. Modica A., Karlsson F. & Mooe T. (2007) Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. Journal of Thrombosis and Haemostasis 5, 507-511.
81. Montalescot G., Wiviott S.D., Braunwald E., Murphy S.A., Gibson C.M., McCabe C.H. & Antman E.M. (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731.
82. Muller I., Besta F., Schulz C., Massberg S., Schonig A. & Gawaz M. (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thrombosis and Haemostasis 89, 783-787.
83. Nicholson N.S., Panzer-Knodle S.G., Haas N.F., Taite B.B., Szalony J.A., Page J.D., Feigen L.P., Lansky D.M. & Salyers A.K. (1998) Assessment of platelet function assays. American Heart Journal 135, S170-S178.
84. Nielsen H.L., Kristensen S.D., Thygesen S.S., Mortensen J., Pedersen S.B., Grove E.L. & Hvas A.M. (2008) Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thrombosis Research 123, 267-273.
85. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., Jinnouchi H., Sugiyama S. & Saito Y. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Journal of the American Medical Association 300, 2134-2141.
86. Papp E., Havasi V., Bene J., Komlosi K., Czopf L., Magyar E., Feher C., Feher G., Horvath B., Marton Z., Alexy T., Habon T., Szabo L., Toth K. & Melegh B. (2005) Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Annals of Pharmacotherapy 39, 1013-1018.
87. Patrono C., Coller B., FitzGerald G.A., Hirsh J. & Roth G. (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 234S-264S.
88. Patrono C., Baigent C., Hirsh J. & Roth G. (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, (8th Edn). Chest, 133, 199S-233S.
89. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A. & Di Sciascio G. (2005) Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111, 2099-2106.
90. Rottlaender D., Scherner M., Schneider T. & Erdmann E. (2007) [Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany]. Deutsche Medizinische Wochenschrift 132, 139-144.
91. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., Goldstein L.B., Gorelick P., Halperin J., Harbaugh R., Johnston S.C., Katzan I., Kelly-Hayes M., Kenton E.J., Marks M., Schwamm L.H. & Tomsick T. (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37, 577-617.
92. Sanderson S., Emery J., Baglin T. & Kinmonth A.L. (2005) Narrative review: aspirin resistance and its clinical implications. Annals of Internal Medicine 142, 370-380.
93. Saw J., Steinhubl S.R., Berger P.B., Kereiakes D.J., Serebruany V.L., Brennan D. & Topol E.J. (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108, 921-924.
94. Serebruany V.L., Midei M.G., Malinin A.I., Oshrine B.R., Lowry D.R., Sane D.C., Tanguay J.F., Steinhubl S.R., Berger P.B., O'Connor C.M. & Hennekens C.H. (2004) Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Archives of Internal Medicine 164, 2051-2057.
95. Shim C.Y., Yoon S.J., Park S., Kim J.S., Choi J.R., Ko Y.G., Choi D., Ha J.W., Jang Y., Chung N., Shim W.H. & Cho S.Y. (2009) The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. International Journal of Cardiology 134, 351-355.
96. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G. & Jilma B. (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. American Heart Journal 157, 148.e 141-148.e 145.
97. Small D.S., Farid N.A., Payne C.D., Weerakkody G.J., Li Y.G., Brandt J.T., Salazar D.E. & Winters K.J. (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology 48, 475-484.
98. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G. & Huisman M.V. (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Archives of Internal Medicine 167, 1593-1599.
99. Soffer D., Moussa I., Harjai K.J., Boura J.A., Dixon S.R., Grines C.L., O'Neill W.W., Roubin G.S. & Moses J.W. (2003) Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheterization and Cardiovascular Interventions 59, 21-25.
100. Staritz P., Kurz K., Stoll M., Giannitsis E., Katus H.A. & Ivandic B.T. (2009) Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y(12)-ADP receptor gene. International Journal of Cardiology 133, 341-345.
101. Storey R.F., Sanderson H.M., White A.E., May J.A., Cameron K.E. & Heptinstall S. (2000) The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. British Journal Haematology 110, 925-934.
102. Szczeklik A., Undas A., Sanak M., Frolow M. & Wegrzyn W. (2000) Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. British Journal Haematology 110, 965-967.
103. Tantry U.S., Bliden K.P. & Gurbel P.A. (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. Journal of the American College of Cardiology 46, 1705-1709.
104. Valgimigli M., Campo G., de Cesare N., Meliga E., Vranckx P., Furgieri A., Angiolillo D.J., Sabate M., Hamon M., Repetto A., Colangelo S., Brugaletta S., Parrinello G., Percoco G. & Ferrari R. (2009) Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119, 3215-3222.
105. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., Harrington R.A., Freij A. & Thorsen M. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 361, 1045-1057.
106. Wang T.H., Bhatt D.L. & Topol E.J. (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal 27, 647-654.
107. Wang T.H., Bhatt D.L., Fox K.A., Steinhubl S.R., Brennan D.M., Hacke W., Mak K.H., Pearson T.A., Boden W.E., Steg P.G., Flather M.D., Montalescot G. & Topol E.J. (2007) An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal 28, 2200-2207.
108. Wiviott S.D. & Antman E.M. (2004) Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109, 3064-3067.
109. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G. & Fox K.K. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 345, 494-502.
110. Zimmermann N., Wenk A., Kim U., Kienzle P., Weber A.A., Gams E., Schror K. & Hohlfeld T. (2003) Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108, 542-547.
111. Zimmermann N., Kurt M., Wenk A., Winter J., Gams E. & Hohlfeld T. (2005) Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? European Journal of Cardio-Thoracic Surgery 27, 606-610.